Danish Study Examines Vaccine Batch Size and Reported Adverse Reactions

The, um, as you can see in front of you on this screen, uh, is the result, the main result of our study.

Uh, it shows from the, uh, official Danish data that we queried f-uh, for the study.

It shows each batch and how many, um, how many adverse reactions were present in each batch.

You can see that along the Y-axis, the vertical axis.

And along the, uh, horizontal axis, you can see how big were the batches. As you can see from the graph, um, some of these batches are very small.

Some of them are very big. And in this case, if we, uh, assume that we would see a normal vaccine, a really good vaccine, something that was very consistently produced, we would see a near perfect line.

One near perfect line. If we, on the other hand, produced a really horrible vaccine, the worst one we could possibly conceive, we would see no line. We would see just scattered dots.

Um, in this case, we see three. Not one, but we see three lines, and they are actually near perfect.

The problem with this is that it's obviously, uh, it, it's something that is completely outside the category of what we should expect to see in adverse, adverse data. That's the main finding of this study. But something that is also very troubling is this shows a system. It shows a structure in the data.

Adverse reactions, error, uh, errors in production are by nature, they're random, but this shows structure.

We do not know yet why, uh, but we are obviously researching this, this issue.

To there are three different types of batches, and every batch gives another, uh, uh risk. And, uh, the, the, the blue one gives the highest mortality risk.

Um, and nobody knew upfront which batch you would get. Nobody knew that there was this difference between these batches. Nobody knew.

But the EMA gets samples of every batch, and they can test it, and they can see whether or not they, they are identical, and that's their job, because their job is to protect us from, uh, mistakes made by pharmaceutical industry.

And that is also something that in a second letter to the AMA, we are going to address. Be sure of that. Uh, as are the things as contamination, uh, by DNA of bacteria in the, in the vaccines, as, uh, are the things that, uh,

Joachim mentioned about are there two databases with adverse, uh, events. Um, um, how come that the, uh, EMA never warned us? And how could it be that they accepted governments to, to campaign, uh, for off-label use?